Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer

por Haslett, K., Koh, P., Hudson, A., Ryder, W.D., Falk, S., Mullan, D., Taylor, B., Califano, R., Blackhall, F., Faivre-Finn, C.
Publicado 2021